The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial).

ABSTRACT: OBJECTIVES:Although effective, direct acting antiviral (DAA) therapies for genotype 1 (GT 1) hepatitis C virus (HCV) have been associated with compliance challenges. Additionally, treatment at predominantly community-based centers has been associated with low retention of patients on treatment and higher dropout rates. The OPTIMAL Phase IV interventional trial (ClinicalTrials.gov Identifier: NCT01405027) was designed to evaluate the impact of an education program for community investigator (CI) sites participating in a Chronic Liver Disease Foundation study treating chronic GT 1 HCV patients. METHODS:This physician educational program was administered by 22 Hepatology Centers of Educational Expertise (HCEE) academic sites to 33 CI sites asked to participate from December 2011 to July 2012.

SUBMITTER: Poordad F 

PROVIDER: S-EPMC4530435 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature